Moderate Evidence
Research Overview
BT5528 Research for Urothelial Cancer
An evidence-based overview of research examining BT5528 in the context of urothelial cancer. This page synthesizes findings from peer-reviewed literature.
Research Summary
BT5528 has shown promising preliminary results in EphA2-positive urothelial cancer patients. Phase 1/2 data reported a 67% overall response rate in this population, with most responses being partial responses. EphA2 is overexpressed in 50-70% of urothelial tumors.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. BT5528 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.